Safety and effectiveness of everolimus in maintenance kidney transplant patients in the real-world setting: results from a 2-year post-marketing surveillance study in Japan

Chapman JR(2011)Chronic calcineurin inhibitor nephrotoxicity-lest we forget Am J Transplant 11 693-697

Nankivell BJ(2004)Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology Transplantation 78 557-565

Borrows RJ(2006)Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Nat Clin Pract Nephrol 2 398-404

Fung CL(2003)Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 178-185

O'Connell PJ(2007)Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients Transplantation 83 1027-1034

Chapman JR(2006)Cardiovascular complications after renal transplantation and their prevention Transplantation 82 603-611

Allen RD(2018)Tailoring tacrolimus therapy in kidney transplantation Expert Rev Clin Pharmacol 11 581-588

Liptak P(2016)Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? Transplant Rev (Orlando) 30 3-12

Ivanyi B(2019)Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study Am J Transplant 19 3018-3034

Kasiske BL(2018)Introduction of everolimus in kidney transplant recipients at a late posttransplant stage World J Transplant 8 150-155

Chapman JR(2011)Chronic calcineurin inhibitor nephrotoxicity-lest we forget Am J Transplant 11 693-697

Nankivell BJ(2004)Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology Transplantation 78 557-565

Borrows RJ(2006)Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Nat Clin Pract Nephrol 2 398-404

Fung CL(2003)Diabetes mellitus after kidney transplantation in the United States Am J Transplant 3 178-185

O'Connell PJ(2007)Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients Transplantation 83 1027-1034

Chapman JR(2006)Cardiovascular complications after renal transplantation and their prevention Transplantation 82 603-611

Allen RD(2018)Tailoring tacrolimus therapy in kidney transplantation Expert Rev Clin Pharmacol 11 581-588

Liptak P(2016)Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? Transplant Rev (Orlando) 30 3-12

Ivanyi B(2019)Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study Am J Transplant 19 3018-3034

Kasiske BL(2018)Introduction of everolimus in kidney transplant recipients at a late posttransplant stage World J Transplant 8 150-155